Recipharm will pay £45 million to Sanofi to acquire Sanofi’s UK inhalation contract manufacturing facility and business “in a bid to expand its inhalation capabilities.” The 125,000 sq m facility in Holmes Chapel has more than 450 employees and manufactures primarily metered dose inhalers and nasal sprays. The site also has DPI development capabilities.
Recipharm will continue to make products currently manufactured at the facility, which include Vectura’s Flutiform, under a long term supply agreement with Sanofi.
According to Recipharm, the acquisition “adds additional inhalation commercial drug product manufacturing capabilities, complementing services already offered by Recipharm’s inhalation development facility in the US.”
Recipharm CEO Thomas Eldered commneted, “Holmes Chapel brings Recipharm an ideal opportunity to accelerate its offering to customers with access to novel of respiratory products. As an already successful CMO with several clients, we look forward to introducing new contracts to Holmes Chapel by utilizing our growing franchise in development services. Treatments for asthma and chronic obstructive pulmonary disease (COPD) are growing at a fast rate and we see many opportunities. The experienced management team and staff have already successfully attracted new customers and we look forward to building on this from the well invested facility.”
Read the Recipharm press release.
